Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
---|---|---|---|---|---|---|---|---|
T. Rowe Price Investment Management, Inc. | 7.2% | $32.1M | 20.3M | T. Rowe Price Investment Management, Inc. | Jun 30, 2025 | |||
Logos Global Management LP | 5.3% | $23.9M | 15.1M | Logos Global Management LP | Jun 30, 2025 | |||
Frazier Life Sciences Public Fund, L.P. | 5.3% | -33.8% | $23.8M | -$11.9M | 15M | -33.4% | Frazier Life Sciences Public Fund, L.P. | Jun 30, 2025 |
SUVRETTA CAPITAL MANAGEMENT, LLC | 5.1% | +17.5% | $22.9M | $3.46M | 14.5M | +17.8% | Suvretta Capital Management, LLC | Jun 30, 2025 |
NOVARTIS PHARMA AG | 4.4% | $14.9M | 12.3M | Novartis Pharma AG | Dec 31, 2024 |
Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
---|---|---|---|---|---|
2025 Q2 | 218M | $277M | -$8.2M | $1.27 | 141 |
2025 Q1 | 224M | $307M | -$9.73M | $1.37 | 151 |
2024 Q4 | 231M | $579M | -$3.89M | $2.51 | 144 |
2024 Q3 | 232M | $633M | +$46.9M | $2.73 | 130 |
2024 Q2 | 204M | $480M | +$260M | $2.36 | 124 |
2024 Q1 | 2.53M | $5.22M | -$8.48M | $2.06 | 11 |
2023 Q4 | 34.3K | $73.1K | +$3.29K | $2.13 | 1 |
2023 Q3 | 71.3M | $140M | -$6.33M | $1.97 | 106 |
2023 Q2 | 74.3M | $205M | -$10.9M | $2.76 | 109 |
2023 Q1 | 78M | $235M | -$11.5M | $3.01 | 114 |
2022 Q4 | 79.6M | $343M | +$2.38M | $4.31 | 103 |
2022 Q3 | 80.2M | $626M | +$33.5M | $7.80 | 80 |
2022 Q2 | 76.6M | $427M | +$21.1M | $5.57 | 81 |
2022 Q1 | 72.8M | $626M | +$45.2M | $8.60 | 77 |
2021 Q4 | 63.6M | $987M | +$63.6M | $15.58 | 58 |
2021 Q3 | 44.1M | $919M | +$919M | $21.22 | 53 |